跳至主要内容
临床试验/JPRN-UMIN000050692
JPRN-UMIN000050692已完成Unknown

A retrospective study to evaluate the impact of proteinuria induced by Atezolizumab plus Bevacizumab on renal function and other renal-related adverse events in patients with unresectable hepatocellular carcinoma. - Atezolizumab plus Bevacizumab-Related Impact on Renal Function and Adverse Events Trial

Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology0 个研究点目标入组 120 人开始时间: 2023年3月31日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients with missing UPCR and eGFR data at baseline (2)Patients with all missing UPCR and eGFR data after starting Atezo+Bev treatment (3)Patients with Child-Pugh Classification Class C at the start of Atezo+Bev treatment (4)Patients deemed ineligible for this study by their physician

研究者

发起方
Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology

相似试验